Protirelin is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | protirelin;24305-27-9;Thyroliberin;Lopremone;Synthetic TRH;Rifathyroin;Thypinone;Thyrotropin-releasing factor;TSH-releasing factor;Protirelina;Protireline;Thyrotropic-releasing factor;5-Oxo-L-prolyl-L-histidyl-L-prolinamide;Protirelinum;THYREL TRH;Relefact TRH;TRH;Abbott 38579;ABBOTT-38579;Protirelin, synthetic;Synthetic tsh-releasing factor;L-Pyroglutamyl-L-histidyl-L-prolinamide;5-oxo-pro-his-pro-nh2;L-Pyroglutamyl-L-histidyl-L-prolineamide;Protireline [INN-French];Protirelinum [INN-Latin];FDA 1725;L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-;Protirelina [INN-Spanish];CCRIS 2593;117217-40-0;Ro 8-6270/9;CHEBI:35940;Relefact TRH (TN);HOLO-TRANSFERRIN;Protirelin [USAN:INN:BAN:JAN];Protirelin tartrate;PROTIRELIN [INN];PROTIRELIN [JAN];EINECS 246-143-4;PROTIRELIN [USAN];(2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;PROTIRELIN [VANDF];5Y5F15120W;NSC-760113;PROTIRELIN [MART.];PROTIRELIN [WHO-DD];L-Pyroglutamyl-L-histidinyl-L-prolinamide;DTXCID403533;DTXSID0023533;PROTIRELIN [ORANGE BOOK];PROTIRELIN [EP MONOGRAPH];24305-27-9 (free base);A-38579;NSC 760113;NCGC00160616-01;Protireline (INN-French);Protirelinum (INN-Latin);Protirelina (INN-Spanish);PROTIRELIN (MART.);(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide;PROTIRELIN (EP MONOGRAPH);(2S)-N-[(2S)-1-[(2S)-2-aminocarbonylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxidanylidene-propan-2-yl]-5-oxidanylidene-pyrrolidine-2-carboxamide;pyroglutamyl-histidyl-prolylamide;Thyrefact;Trh-cambridge;Protirelin?;trh-sr;Synthetic TRF;UNII-5Y5F15120W;Human Transferrin;Relefact-TRH;TRH, Relefact;Stimu-TSH;Thyrotropin-releasing factor (pig);(2S)-N-((2S)-1-((2S)-2-aminocarbonylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxidanylidene-propan-2-yl)-5-oxidanylidene-pyrrolidine-2-carboxamide;(2S)-N-((2S)-1-((2S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide;PR 546;PR-546;Synthetic thyrotropin-releasing factor;Pyr-His-Pro-NH2;Abbott38579;PyroGlu-His-prolinamide;Thyroliberin TRH Merck;TSH-RF;TRH [MI];Thyrotropin Releasing Factor;CHEMBL1472;SCHEMBL33419;[3H]-TRH;GTPL2139;GTPL3836;Siderophilin;partially saturated;pyroglutamyl-histidyl-prolinamide;Protirelin (JP18/USAN/INN);SCHEMBL19825647;[3H]TRH (human, mouse, rat);V04CJ02;Thyrotropin Releasing Hormone TRH;BCP12450;HY-P0002;Synthetic thyrotopin releasing factor;Tox21_111939;BDBM50072394;s4680;AKOS015994636;AKOS040759052;CCG-268193;DB09421;FP33965;HS-2023;Protirelin;Thyrotropin-Releasing Hormone;(2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;DA-64226;L-Pyroglutamyl-L-histidyl-L-proline amide;CAS-24305-27-9;NS00006015;C03958;C74244;D00176;Prolinamide, 5-oxo-L-prolyl-L-histidyl-, L-;L-PYROGLUTAMYL-L-HISTIDYL-L-PROLINE-AMIDE;(Pyro)-L-glutamic acid-L-histidine-L-proline-NH2;A858244;EN300-27034140;Q24726011;Prolinamide, 1-[N-(5-oxo-L-prolyl)-L-histidyl]-, L-;pyroGlu-His-Pro-NH2 (or 5-oxo-L-prolyl-L-histidyl-L-prolinamide);(2S)-1-[(2S)-3-(1H-IMIDAZOL-4-YL)-2-{[(2S)-5-OXOPYRROLIDIN-2-YL]FORMAMIDO}PROPANOYL]PYRROLIDINE-2-CARBOXAMIDE;(2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanoyl]pyrrolidine-2-carboxamide;(2S)-1-[(2S)-3-(imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanoyl]pyrrolidine-2-carboxamide;(2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]-5-keto-pyrrolidine-2-carboxamide;1-(3-(1H-Imidazol-5-yl)-2-([(5-oxo-2-pyrrolidinyl)carbonyl]amino)propanoyl)-2-pyrrolidinecarboxamide #;1-[3-(1H-4-imidazolyl)-2-(5-oxotetrahydro-1H-2-pyrrolylcarboxamido)propanoyl]tetrahydro-1H-2-pyrrolecarboxamide;2-Pyrrolidinecarboxamide, N-[1-[(2-carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-,;2-Pyrrolidinecarboxamide, N-[1-[(2-Carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-, (S,S,S)-;246-143-4; |
M.F/Formula | C16H22N6O4 |
M.W/Mr. | 362.38 |
Sequence | One Letter Code:XHP Three Letter Code:H-Pyr-His-Pro-NH2 |
Application | TRH has been used clinically for the treatment of spinocerebellar degeneration and disturbance of consciousness in humans. |
Appearance | Solid powder |
Target | Thyroid Hormone Receptor |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1 |
InChI Key | XNSAINXGIQZQOO-SRVKXCTJSA-N |
2. High fat diet and GLP-1 drugs induce pancreatic injury in mice
3. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.